EUVIMEDEUVIMED entdecken
Open Access

Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity

Kelly E W Carufe iD, Nicholas G Economos, Peter M Glazer

Nucleic Acid Therapeutics · 01.10.2024 · 34 (5) · 245-256

DOI: 10.1089/nat.2024.0007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 16.10.2024. Verfasst von Kelly E W Carufe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Peptide Nucleic Acids, RNA, Guide, CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although CRISPR-Cas9 gene therapies have proven to be a powerful tool across many applications, improvements are necessary to increase the specificity of this technology. Cas9 cutting in off-target sites remains an issue that limits CRISPR’s application in human-based therapies. Treatment of autosomal dominant diseases also remains a challenge when mutant alleles differ from the wild-type sequence by only one base pair. Here, we utilize synthetic peptide nucleic acids (PNAs) that bind selected spacer sequences in the guide RNA (gRNA) to increase Cas9 specificity up to 10-fold. We interrogate variations in PNA length, binding position, and degree of homology with the gRNA. Our findings reveal that PNAs bound in the region distal to the protospacer adjacent motif (PAM) site effectively enhance specificity in both on-target/off-target and allele-specific scenarios. In addition, we demonstrate that introducing deliberate mismatches between PNAs bound in the PAM-proximal region of the gRNA can modulate Cas9 activity in an allele-specific manner. These advancements hold promise for addressing current limitations and expanding the therapeutic potential of CRISPR technology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsPeptide Nucleic AcidsRNA, Guide, CRISPR-Cas SystemsGene EditingHumansAllelesCRISPR-Associated Protein 9HEK293 Cells

Stichwörter der Autor:innen

CRISPR-Cas9allele specificityoff-targetpeptide nucleic acidsregulationspecificity

Substanzen

Peptide Nucleic AcidsRNA, Guide, CRISPR-Cas SystemsCRISPR-Associated Protein 9

Autor:innen und Institutionen

  • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Kelly E W Carufe

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Carufe, K. E. W., Economos, N. G., & Glazer, P. M. (2024). Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity. Nucleic Acid Therapeutics, 34(5), 245-256. https://doi.org/10.1089/nat.2024.0007

Vancouver

Carufe KEW, Economos NG, Glazer PM. Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity. Nucleic Acid Therapeutics. 2024;34(5):245-256. doi:10.1089/nat.2024.0007

BibTeX
@article{Carufe2024,
  author = {Carufe, Kelly E W and Economos, Nicholas G and Glazer, Peter M},
  title = {Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity},
  journal = {Nucleic Acid Therapeutics},
  year = {2024},
  volume = {34},
  number = {5},
  pages = {245--256},
  doi = {10.1089/nat.2024.0007}
}
Kostenlos starten →